A Multi-Centre, Single-Blind Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects
Phase of Trial: Phase II
Latest Information Update: 16 May 2018
Price : $35 *
At a glance
- Drugs Cat SPIRE (Primary)
- Indications Asthma; Hypersensitivity; Rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Circassia
- 06 Mar 2017 Results assessing the efficacy, safety and tolerability of Cat-PAD in children, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.